MASSDEVICE ON CALL — Medtronic Inc. (NYSE:MDT) faces new heat over the Infuse bone growth product, this time for allegations that the therapy caused excess bone growth in the spinal canal of 70 percent of patients in an independent clinical trial.
In what has become a familiar cry against the Infuse product, doctors on the company’s payroll were accused of concealing vital information from published studies.